Bibliography

ESMO 2024: Prof. Reichardt

• Benjamin RS, et al. Cancer. 1974;33(1):19–27.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Joensuu H, et al. N Engl J Med. 2001;344(14):1052–1056.
• Maki RG, et al. Int J Cancer. 2002;100(6):623–626.
• van der Graaf WT, et al. Lancet. 2012;379(9829):1879–1886.

ESMO 2024: Dr Gronchi

• Bellefkih FZ, et al. Cancer/Radiothérapie. 2023;27:622–637.
• Calderillo-Ruíz G, et al. Neoplasia. 2024;48:100959.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Fairweather M, et al. Ann Surg. 2018;268(2):296–302.
• Gelderblom H, et al. J Clin Oncol. 2023;41(16 suppl):11585.
• Gruber L, et al. Biomedicines. 2022;10(11):2899.
• Joensuu H, et al. Lancet Oncol. 2012;13(3):265–274.
• Mastboom MJL, et al. Acta Orthop. 2017;88(6):688–694.
• Mastboom MJL, et al. Lancet Oncol. 2019;20:877–886.
• Nishida T, et al. Cancer. 2016;122(20):3110–3118.
• Rathmann N, et al. J Vasc Interv Radiol. 2015;26:231–238.
• Schipani A, et al. Genes. 2023;14:646–662.
• Serrano C, et al. Ther Adv Med Oncol. 2023;15:17588359231192388.
• Stacchiotti S, et al. Cancer Treat Rev. 2023;112:102491.

ESMO 2024: Prof. Gelderblom

• Blay JY, et al. Ann Oncol. 2008;19(4):821–822.
• Brooke B, et al. Drug Des Devel Ther. 2020;14:1693–1704.
• Cassier PA, et al. Cancer. 2012;118(6):1649–1655.
• ClinicalTrials.gov. NCT04731675. Available at https://clinicaltrials.gov/study/NCT04731675. Accessed October 2025.
• ClinicalTrials.gov. NCT05417789. Available at https://clinicaltrials.gov/study/NCT05417789. Accessed October 2025.
• ClinicalTrials.gov. NCT05804045. Available at https://clinicaltrials.gov/study/NCT05804045. Accessed October 2025.
• Gelderblom H, et al. Lancet Oncol. 2018;19(5):639–648.
• Mastboom MJL, et al. Acta Orthop. 2017;88(6):688–694.
• Mastboom MJL, et al. Interact J Med Res. 2018;7(1):e4.
• Mastboom MJL, et al. Lancet Oncol. 2019;20:877–886.
• Spierenburg G, et al. Eur J Cancer. 2022;173:219–228.
• Tap WD, et al. Future Oncol. 2024;20(10):593–601.
• Tap WD, et al. Lancet. 2019;394(10197):478–487.
• TURALIO^® Prescribing Information. January 2025.
• Verspoor FGM, et al. Sci Rep. 2019;9:14551.
• West RB, et al. Proc Natl Acad Sci USA. 2006;103(3):690–695.

ESMO 2024: Prof. Le Cesne

• Bauer S, et al. Front Oncol. 2021;11:672500.
• Bauer S, et al. J Clin Oncol. 2022;40(34):3918–3928.
• Bauer S, et al. J Clin Oncol. 2022;40(34):3918–3928 (Suppl).
• Bauer S, et al. J Clin Oncol. 2023;41(suppl 36). Abstr 397784.
• Blanke C, et al. J Clin Oncol. 2008;26(4):620–625.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• ClinicalTrials.gov. NCT03556384. Available at https://clinicaltrials.gov/study/NCT03556384. Accessed October 2025.
• ClinicalTrials.gov. NCT04193553. Available at https://clinicaltrials.gov/study/NCT04193553. Accessed October 2025.
• ClinicalTrials.gov. NCT04936178. Available at https://clinicaltrials.gov/study/NCT04936178. Accessed October 2025.
• ClinicalTrials.gov. NCT05152472. Available at https://clinicaltrials.gov/study/NCT05152472. Accessed October 2025.
• ClinicalTrials.gov. NCT05208047. Available at https://clinicaltrials.gov/study/NCT05208047. Accessed October 2025.
• Cousin S, et al. Presented at: ESMO 2023. Abstract 1920MO.
• Demetri GD, et al. Lancet. 2006;368(9544):1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• George S, et al. Presented at ASCO 2023. Abstract TPS11582.
• Heinrich M, et al. JAMA Oncol. 2017;3(7):944–952.
• Heinrich M, et al. Lancet Oncol. 2020;21(7):935–946.
• Heinrich M, et al. Nat Med. 2024; doi: https://doi.org/10.1038/s41591-023-02734-5.
• Janeway KA, et al. Pediatr Blood Cancer. 2009;52(7):767–771.
• Kang YK, et al. J Clin Oncol. 2021;39(28):3128–3139.
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949.
• Martin-Broto J, et al. Mol Cancer. 2023;22(1):127.
• Mohammadi M, Gelderblom H. Expert Opin Investig Drugs. 2021;30(2):143–152.
• Patrikidou A, et al. Eur J Cancer. 2016;52:173–180.
• QINLOCK^® Summary of Product Characteristics. October 2024.
• Qiu H, ASCO J Clin Oncol. 2022;40(16):11513.
• Salem ME, et al. Mol Cancer Res. 2018;16(5):805–812.
• Singh AS, et al. Clin Cancer Res. 2022;28:84–94.
• Smith B, et al. Cancer Cell. 2019;35(5):738–751.
• STIVARGA^® Summary of Product Characteristics. July 2025.
• SUTENT^® Summary of Product Characteristics. March 2025.
• Tap WD, et al. Oral presentation at ASCO 2023.
• Vallilas C, et al. Int J Med Sci. 2021;22(2):493.
• Verma S, et al. Fur Sci OA. 2021; FSO676.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.
• Yeh CN, et al. Oncotarget. 2017;8(27):44121–44130.

ESMO 2023: Dr Napolitano

• Blanke CD, et al. Clin Oncol. 2008;26(4):626–632.
• Blay JY, et al. Nat Rev Dis Primers. 2021;7(1):22.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Demetri GD, et al. N Engl J Med. 2002;347(7):472–480.
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). J Clin Oncol. 2010;28(7):1247–1253.
• Grant G. Brain Res Rev. 2007;55:490–498.
• Heinrich MC, et al. Clin Sarcoma Res. 2019;9:3.
• Hirota S, et al. Science. 1998;279(5350):577–580.
• Joensuu H, et al. N Engl J Med. 2001;344(14):1052–1056.
• Joensuu H. Hum Pathol. 2008;39(10):1411–1419.
• Joensuu H, et al. JAMA Oncol. 2020;6(8):1241–1246.
• Klug LR, et al. Nat Rev Clin Oncol. 2022;19(5):328–341.
• Mostafa RM, et al. World J Gastroenterol. 2010;16(26):3239–3248.
• Serrano C, et al. Br J Cancer. 2019;120:612–620.
• TIME. Drugs that fight cancer. 28 May 2001 [Cover]. Available at https://content.time.com/time/covers/0,16641,20010528,00.html. Accessed October 2025.
• van Oosterom AT, et al. Lancet. 2001;358(9291):1421–1423.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.
• Vincenzi B, et al. Clin Cancer Res. 2022;28(8):1672–1679.

ESMO 2023: Dr Watson

• Bauer S, et al. Front Oncol. 2021;11:672500.
• Bauer S, et al. Presented at the American Society of Clinical Oncology Plenary Series; 24 January 2023; Online.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Blay JY, et al. Nat Rev Dis Primers. 2021;7:22.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Cohen P, et al. Nat Rev Drug Discov. 2021;20:551–569.
• Demetri GD, et al. Lancet. 2006;368(9544):1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• Gardino A, et al. Mol Cell Oncol. 2018;5(3):e1435183.
• George S, et al. Oncologist. 2021;26(4):e639–e649.
• Gramza A, et al. Clin Cancer Res. 2009;15(24):7510–7518.
• Heinrich M, et al. J Clin Oncol. 2006;24(29):4764–4774.
• Heinrich M, et al. J Clin Oncol. 2008;26(33):5352–5359.
• Heinrich M, et al. Oral presentation at the Connective Tissue Oncology Society Annual Meeting 2018; 15 November 2018; Rome, Italy: #3027631.
• Heinrich M, et al. Lancet. 2020;21(7):935–946.
• IUPHAR/BPS Guide to Pharmacology. Ripretinib. Available at https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9175. Accessed October 2025.
• Jones R, et al. Eur J Cancer. 2021;145:132–142.
• Kang YK, et al. J Clin Oncol. 2021;39(28):3128–3139.
• Le Cesne A. Oral presentation at the ESMO Sarcoma and GIST Symposium 2022; 31 Jan – 2 Feb 2022; Virtual.
• Liegl B, et al. J Pathol. 2008;216(1):64–74.
• Patrikidou A, et al. Eur J Cancer. 2016;52:173–180.
• Raul C, et al. Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors. 2023. Available at https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-prognosis-of-gastrointestinal-stromal-tumors/print. Accessed October 2025.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.

ESMO 2023: Dr Serrano

• Bauer S, et al. ASCO Plenary Series: January 2023 Session.
• Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342.
• ClinicalTrials.gov. NCT02164240. Available at https://clinicaltrials.gov/study/NCT02164240. Accessed October 2025.
• ClinicalTrials.gov. NCT03465722.  Available at https://www.clinicaltrials.gov/study/NCT03465722. Accessed October 2025.
• ClinicalTrials.gov. NCT03673501. Available at https://www.clinicaltrials.gov/study/NCT03673501. Accessed October 2025.
• ClinicalTrials.gov. NCT05734105. Available at https://clinicaltrials.gov/ct2/show/NCT05734105. Accessed October 2025.
• George S, et al. 2023 ASCO Annual Meeting: TPS11582.
• Heitzer E, et al. Nat Rev Genet. 2019;20(2):71–88.
• Marquart J, et al. JAMA Oncol. 2018;4(8):1093–1098.
• Merker JD, et al. J Clin Oncol. 2018;36(16):1631–1641.
• Serrano C, et al. Clin Cancer Res. 2019;25(24):7287–7293.
• Serrano C, et al. 2022 ASCO Annual Meeting.
• Serrano C, et al. Ann Oncol. 2023;34(7):615–625.
• Serrano C, et al. Ann Oncol. 2023;34(7):615–625 Supplementary Material.
• Serrano C, Fletcher JA. Oncotarget. 2019;10(59):6286–6287.
• Serrano C, George S. Clin Cancer Res. 2020;26(19):5078–5085.

ESMO Sarcoma and Rare Cancers Congress 2023: Prof. Bauer

• Bauer S, et al. Int J Cancer. 2005;117:316–325.
• Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342.
• Bauer S, et al. J Clin Oncol. 2022;40(34):3918–3928.
• Bauer S, et al. Presented at ASCO Plenary Series; January 2023.
• Bauer S, et al. Oral presentation at ASCO Plenary Series; January 2023.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Casali P, et al. J Clin Oncol. 2017;35:1713–1720.
• Corless CL, et al. J Clin Oncol. 2005;23(23):5357–5364.
• Corless C, et al. Nat Rev Cancer. 2011;11(12):865–878.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• Evans EK, et al. Sci Transl Med. 2017;9(414):eaao1690.
• Garner AP, et al. Clin Cancer Res. 2014;20(22):5745–5755.
• GLIVEC^® Summary of Product Characteristics. August 2025.
• Heinrich MC. ASCO; 2010: educational session.
• Hornick JL, et al. Hum Pathol. 2007;38(5):679–687.
• Mendel DB, et al. Clin Cancer Res. 2003;9(1):327–337.
• Miettinen M, et al. Am J Surg Pathol. 2006;30(1):90–96.
• Miettinen M, et al. Am J Surg Pathol. 2011;35(11):1712–1721.
• Nemunaitis J, et al. Future Oncol. 2020;16(1):4251–4264.
• QINLOCK^® Summary of Product Characteristics. October 2024.
• Schwartz GK. J Clin Oncol. 2022;40(34):3903–3906.
• Serrano C, et al. Presented at ASCO Annual Meeting; June 2022; Illinois, USA.
• Smith BD, et al. Cancer Cell. 2019;35:738–751.
• STIVARGA^® Summary of Product Characteristics. July 2025.
• SUTENT^® Summary of Product Characteristics. March 2025.
• Wardelmann E, et al. Lancet Oncol. 2005;6:249–251.

ESMO Sarcoma and Rare Cancers Congress 2023: Doctor Benson

• Blay JY, et al. Lancet Oncol. 2020;21:923–934.
• GLIVEC^® Summary of Product Characteristics. August 2025.
• Radboud University Medical Center Nijmegen. Evaluation of the value of therapeutic drug monitoring to predict treatment outcome in terms of survival and toxicity in patients with solid tumors treated with imatinib, sunitinib andpazopanib. UK REC approval date: 23/02/2021.
• Peña M, et al. Blood Adv. 2021;5(17):3344–3353.
• Poster presentation at British Sarcoma Group Annual Conference, March 2023.
• Serrano C, et al. Oral Presentation at the ESMO World Congress on Gastrointestinal Cancer; 1–4 July 2020; Virtual meeting.
• STIVARGA^® Summary of Product Characteristics. July 2025.
• Su Yin Lim, et al. Poster presented at ESMO Sarcoma and Rare Cancers Annual Congress; March 2023.
• SUTENT^® Summary of Product Characteristics. March 2025.
• von Mehren, et al. Poster presented at ESMO Virtual Congress; 16–21 September 2021.

ESMO Sarcoma and Rare Cancers Congress 2023: Prof. Vincenzi

• Joensuu H, et al. Lancet Oncol. 2012;13(3):265–274.
• Demetri GD, et al. J Natl Compr Canc Netw. 2010;8 Suppl 2(0 2):S1–44.

ESMO 2022: Prof. Le Cesne

• Atiq MA, et al. Modern Pathol. 2021;34:95–10.
• AYVAKYT^® Summary of Product Characteristics. April 2024.
• Bauer S, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR–21–1864.
• Bauer S, et al. J Clin Oncol. 2022. DOI: 10.1200/JCO.22.00294.
• Bauer S. et al. J Clin Oncol. 2022;JCO2200294. DOI: 10.200/JCO.22.00294.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):620–625.
• Blay JY, et al. Lancet Oncol. 2015; 16(5):550–560.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934. Supplementary appendix.
• Blay JY, et al. Poster presented at 17th Journées Annuelles Du GSF-GETO; June 29-July 1 2022.
• Callejo et al. Target Oncol. 2021; 16 (4): 485-492. doi: 10.1007/s11523-021-00820-7.
• Casali PG, et al. J Clin Oncol. 2017;35(15):1713–1720.
• Casali PG, et al. Ann Oncol. 2021 Sep 21;S0923–7534(21)04480-X.
• Casali PG, et al. Annals Oncol. 2021; 33(1):20–33.
• Cassier PA, et al. Clin Cancer Res. 2012;15(18):4458–4464.
• ClinicalTrials.gov. NCT02638766. Available at: https://clinicaltrials.gov/ct2/show/NCT02638766. Accessed October 2025.
• ClinicalTrials.gov NCT05009927. Available at: https://clinicaltrials.gov/ct2/show/NCT05009927. Accessed October 2025.
• Clinicaltrials.gov NCT03673501. Available at: https://clinicaltrials.gov/ct2/show/NCT03673501. Accessed October 2025.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. Lancet. 2013; doi: 10.1016/S0140-6736(12)61857-1.
• Demetri G, Albert CM, Tan DSW et al. Larotrectinib efficacy and safety in patients with TRK fusion sarcomas. CTOS 2019.
• Drilon A, et al. N Engl J Med. 2018;378:731–739.
• GLIVEC^® Summary of Product Characteristics. August 2025.
• Grunewald S, et al. Cancer Dis. 2021; doi: 10.1158/2159-8290.CD-20-0487.
• Heinrich MC, et al. JAMA Oncol. 2017;3(7):944–952.
• Heinrich MC, et al. J Clin Oncol. 2017; doi:0.1200/JCO.2017.35.15_suppl.11011.
• Heinrich MC, et al. Lancet Oncol. 2020;21(7):935–946.
• Hemming ML, et al. Ann Oncol. 2018;29:2037.
• Hong D, et al. Cancer Disc. 2016; doi: 10.1158/2159-8290.CD–16–0050.
• Janeway KA et al. Pediatr Blood Cancer. 2009;52(7):767–771.
• Janku F, et al. J Clin Oncol. 2020;38:3294–3303.
• Kang Y-K, et al. J Clin Oncol. 2021; 39(28):3128–3139.
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949.
• Lopes LF, et al. J Cell Mol Med. 2010;14:42.
• Lostes-Bardaji MJ, et al. Ther Adv Med Oncol. 2021;13:1758835920986498.
• MetaGIST. J Clin Oncol. 2010;28(7):1247–1253.
• QINLOCK^® Summary of Product Characteristics. October 2024.
• Qiu H et al. Oral Presentation Presented at ASCO Annual Meeting; June 3-7, 2022; Chicago,IL.
• Patrikidou A, et al. EJC. 2016;52:173–180.
• Rivera et al, AACR 2021.
• Salem ME, et al. Mol Cancer Res. 2018; doi: 10.1158/1541-7786.MCR–17–0735.
• Shi SS, et al. Histopathology. 2017;71(4):553–561.
• Smith BD, et al. Cancer cell. 2019;35(5):738–751.e9.
• Vallilas C, et al. IJMS. 2021;22(2)493.
• Vincenzi B, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-1665.
• Wagner et al, JAMA Oncol. 2021.
• Zalcberg JR. Ther Adv Gastroenterol. 2021;14:1–12.

ESMO 2022: Prof. Italiano

• Blay JY, et al. Lancet Oncol. 2020; 21: 923–934.
• Call et al. Clin Sarcoma Res. 2019;9:4.
• Carbajal-López EB et al. J Cancer Educ. 2022;37(3):668–674.
• Casali PG, et al. J Clin Oncol. 2017;35(15):1713–1720.
• Clinicaltrials.gov NCT03963544. Available at: https://clinicaltrials.gov/study/NCT03963544. Accessed October 2025.
• Foo T, et al. Target Oncol. 2022;17(2):95–110.
• George S, et al. Eur J Cancer. 2021;155:236–244.
• GLIVEC^® Summary of Product Characteristics. August 2025.
• Heinrich M, et al. Poster Presented at ASCO 2020 Virtual meeting; Data on File, 2022.
• Ma et al. Cancer Epidemiol Biomarkers Prev. 2015;24(1):298–302.
• QINLOCK^® Summary of Product Characteristics. October 2024.
• Reichardt P, et al. Cancer. 2015;121(9):1405–1413.
• Poole CD, et al. Gastric Cancer. 2015;18(3):627–634.
• Schvartsman et al. Sci Rep. 2017;7(1):9519.
• STIVARGA^® Summary of Product Characteristics. July 2025.
• SUTENT^® Summary of Product Characteristics. March 2025.
• Xie et al. Adv Ther. 2019;36(8):1986–1998.

ESMO 2022: Prof. Reichardt

• Blay J et al. Lancet Oncol. 2020;21(7):923–934.
• Demetri GD et al. Lancet. 2006;3681329–1338.
• Demetri GD et al. Lancet. 2013;381(9863):295–302.
• European Medicines Agency (EMA) assessment report, EMA/CHMP/55164/2021.
• Kang Y-K et al. Lancet Oncology. 2013;14(12):1175–1182.
• QINLOCK^® Summary of Product Characteristics. October 2024.
• Reichardt P et al. Ann Oncol. 2012;23:1680–1687.
• Reichardt P et al. CTOS 2012.

ESMO Sarcoma and GIST Symposium 2022: Prof. Gronchi

• An HJ, et al. Ann Surg Oncol. 2013;20(13):4212–4218.
• Bauer S, et al. Eur J Surg Oncol. 2014;40:412–419.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):626–632.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• DeMatteo RP, et al. Ann Surg. 2007;245(3):347–352.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. Lancet. 2013;381:295–302.
• Du CY, et al. Eur J Cancer. 2014;50:1772–1778.
• Fairweather M, et al. Ann Surg. 2018;268(2):296–302.
• Fiore M, et al. Eur J Surg Oncol. 2009;35(7):739–745.
• Gronchi A, et al. Ann Surg. 2007;245(3):341–346.
• Gronchi A, et al. Ann Surg Oncol. 2012;19:3361–3367.
• Gronchi A, et al. Ann Surg Oncol. 2012;19:1051–1055.
• Haller F, et al. Ann Surg Oncol. 2007;14:526–532.
• Heinrich MC, et al. Lancet Oncol. 2020;21:935–946.
• Joensuu H, et al. Lancet Oncol. 2012;13:265–274.
• Le Cesne A, et al.Lancet Oncol. 2010;11(10):942–949.
• Nannini M, et al. J Med Genet. 2013;50:653–661.
• Park SJ, et al. Ann Surg Oncol. 2014;21(13):4211–4217.
• QINLOCK^® Summary of Product Characteristics. October 2024.
• Raut CP, et al. J Clin Oncol. 2006;24(15):2325–2331.
• Rubiò-Casadevall J, et al. Ann Surg Oncol. 2015;22(9):2948–2957.
• Rutkowski P, et al. Ann Surg Oncol. 2013;20:2937–2943.
• Sharma AK, et al. Clin Cancer Res. 2021;27:5334–5342.
• STIVARGA^® Summary of Product Characteristics. July 2025.
• SUTENT^® Summary of Product Characteristics. March 2025.
• van Glabbeke M, et al.J Clin Oncol. 2005;23(24):5795–5804.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.

ESMO Sarcoma and GIST Symposium 2022: Dr Serrano

• Evans EK, et al. Sci Transl Med. 2017;1;9(414):eaao1690.
• Gramza AW, et al. Clin Cancer Res. 2009;15(24):7510–7518.
• Lopes LF, et al. J Cell Mol Med. 2010;14(1–2):43–50.
• Mariño-Enríquez A, Bovée J. Surg Pathol Clin. 2016;9(3):457–473.
• Nannini M, et al. BMC Cancer. 2014; doi: 10.1186/1471-2407-14-685.
• Oppelt PJ, et al. J Gastrointest Oncol. 2017;8(3):466–473.
• Ordog T, et al. Stem Cells Transl Med. 2015;4(7):702–707.
• Serrano C, George S. Ther Adv Med Oncol. 2014;6(3):115–127.
• Serrano C, et al. J Clin Oncol. 2015;33(22):e93–e96.
• Serrano C, et al. Br J Cancer. 2019;120(6):612–620.
• Serrano C, George S. Clin Cancer Res. 2020;26:5078–5085.
• Serrano C, et al. BMC Cancer. 2020; doi: 10.1186/s12885-020-6597-x.
• Serrano C. Curr Op Oncol. 2021;33:323–328.
• Smith BD, et al. Cancer Cell. 2019;35(5):738–751.e9.
• Wozniak A, et al. Clin Can Res. 2014;20(23):6105–6116.
• Yan W, et al. Chin J Cancer. 2016; doi: 10.1186/s40880-016-0131-1.

ESMO Sarcoma and GIST Symposium 2022: Prof. Le Cesne

• Atiq MA, et al. Modern Pathol. 2021;34:95–103.
• Bauer S, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-1864.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):620–625.
• Blay JY, et al. Lancet Oncol. 2015;16(5):550–560.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934. Supplementary appendix.
• Callejo A, et al. Target Oncol. 2021;16 (4):485–492.
• Casali PG, et al. J Clin Oncol. 2017;35(15):1713–1720.
• Casali PG, et al. Ann Oncol. 2022;33:20–33.
• Cassier PA, et al. Clin Cancer Res. 2012;15(18):4458–4464.
• ClinicalTrials.gov. NCT02638766. Available at https://clinicaltrials.gov/ct2/show/NCT02638766. Accessed October 2025.
• Deciphera Press Release. November 2021.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. J Clin Oncol. 2009;27(25):4188–4196.
• Demetri GD, et al. Presented at European Society for Medical Oncology; 27 September – 1 October 2013; Amsterdam, Netherlands.
• Demetri GD, et al. Lancet. 2013; doi: 10.1016/S0140-6736(12)61857-1.
• Demetri G, et al. Presented at Connective Tissue Oncology Society; 15 November 2019; Tokyo, Japan.
• Drilon A, et al. N Engl J Med. 2018;378:731–739.
• Grunewald S, et al. Cancer Dis. 2021; doi: 10.1158/2159-8290.CD-20-0487.
• Heinrich MC, et al. JAMA Oncol. 2017;3(7):944–952.
• Heinrich MC, et al. J Clin Oncol. 2017; doi: 10.1200/JCO.2017.35.15_suppl.11011.
• Heinrich MC, et al. Lancet Oncol. 2020;21(7):935–946.
• Hong D, et al. Cancer Disc. 2016; doi: 10.1158/2159-8290.CD-16-0050.
• Houk BE, et al. Cancer Chemother Pharmacol. 2010;66(2):357–371.
• Kang YK, et al. J Clin Oncol. 2021;39(26):2903–2913.
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949.
• Lostes-Bardaji MJ, et al. Ther Adv Med Oncol. 2021;13:1758835920986498.
• MetaGIST. J Clin Oncol. 2010;28(7):1247–1253.
• Patrikidou A, et al. EJC. 2016;52:173–180.
• Salem ME, et al. Mol Cancer Res. 2018; doi: 10.1158/1541-7786.MCR-17-0735.
• Shi SS, et al. Histopathology. 2017;71(4):553–561.
• Vallilas C, et al. IJMS. 2021;22(2)493.
• Verweij J, et al. Lancet. 2014;364(9440):1127–1134.
• Vincenzi B, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-1665.
• von Mehren M, et al. Oral Presentation at European Society for Medical Oncology; 27 September – 1 October 2019; Barcelona, Spain.
• Zalcberg JR, et al. Oncologist. 2021; doi: 10.1002/onco.13917.
• Zalcberg JR. Ther Adv Gastroenterol. 2021;14:1–12.

ESMO 2021: Prof. Reichardt

• Akahoshi K, et al. World J Gastroenterol. 2018;24(26):2806–2817.
• Antonescu CR, et al. Clin Cancer Res. 2005;11(11):4182–4190.
• Astolfi A, et al. Int J Mol Sci. 2020;21(9):3313.
• AYVAKYT^® Summary of Product Characteristics. April 2024.
• Babaei MA, et al. Drug Des Devel Ther. 2016;10:2443–2459.
• Call J, et al. BMC Cancer. 2012;12:90.
• Casali PG, et al. Annal Oncol. 2018;29(Suppl 4):iv68–iv78.
• Casali PG, et al. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019:895–906.
• Corless CL. Mod Pathol. 2014;27(Suppl 1):S1–S16.
• DeMatteo RP, et al. Ann Surg. 2000;231(1):51–58.
• Demetri GD, et al. N Engl J Med. 2002;347(7):472–480.
• Demetri GD, et al. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1–41; quiz S42–S44.
• Demetri GD. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 9th ed; Philadelphia, PA: Wolters Kluwer; 2011:1060–1073.
• Duffaud F, Le Cesne A. F1000Res. 2017; doi: 10.12688/f1000research.11118.1.
• Edmonson JH, et al. Cancer Invest. 2002;20(5–6):605–612.
• Foo WC, et al. Clin Med Insights Pathol. 2012;5:23–33.
• George S, et al. Poster presented at American Society of Clinical Oncology; 1–5 June 2018; Chicago, IL; abstract #11511.
• GLIVEC^® Summary of Product Characteristics. August 2025.
• Gramza AW, et al. Clin Cancer Res. 2009;15(24):7510–7518.
• Heinrich MC, et al. Science. 2003;299(5607):708–710.
• Hemming ML, et al. Ann Oncol. 2018;29(10):2037–2045.
• Hirota S, et al. Science. 1998;279(5350):577–580.
• Joensuu H, et al. Lancet Oncol. 2012;13(3):265–274.
• Joensuu H, et al. JAMA Oncol. 2020;6:1241–1246.
• Laurini JA, et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor (GIST). College of American Pathologists website. Available at https://documents.cap.org/protocols/cp-gist-2017-v4001.pdf. Accessed October 2025.
• Lennartsson J, et al. Physiol Rev. 2012;92(4):1619–1649.
• Li K, et al. Oncotarget. 2017;8(36):60589–60604.
• Lopes LF, Bacchi CE. J Cell Mol Med. 2010;14(1–2):42–50.
• Lostes-Bardaji MJ, et al. Ther Adv Med Oncol. 2021; doi: 10.1177/1758835920986498.
• Mazur MT, Clark HB. Am J Surg Pathol. 1983;7(6):507–519.
• MedlinePlus. Neurofibromatosis type 1. Available at https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1. Accessed October 2025.
• Miettinen M, Lasota J. Semin Diagn Pathol. 2006;23(2):70–83.
• NCCN guidelines. Gastrointestinal stromal tumors (GIST). Available at https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1507. Accessed October 2025.
• Oppelt PJ, et al. J Gastrointest Oncol. 2017;8(3):466–473.
• Ordog T, et al. Stem Cells Transl Med. 2015;4(7):702–707.
• Parab TM, et al. J Gastrointest Oncol. 2019;10(1):144–154.
• Patel N, Benipal B. Cureus. 2019; doi: 10.7759/cureus.4120.
• QINLOCK^® Prescribing Information. May 2025.
• Quek R, George S. Hematol Oncol Clin North Am. 2009;23(1):69–78.
• Rammohan A, et al. World J Gastrointest Oncol. 2012;5(6):102–112.
• Raut CP, et al. JAMA Oncol. 2018;4(12):e184060.
• Ricci R. Hered Cancer Clin Pract. 2016; doi: 10.1186/s13053-016-0055-4.
• Smith BD, et al. Cancer Cell. 2019;35(5):738–751.
• Soreide K, et al. Cancer Epidemiol. 2016;40:39–46.
•  STIVARGA^® Prescribing Information. February 2025.
• SUTENT^® Prescribing Information. August 2021.
• TudorRose Consulting Pty Ltd. Data on file. Orphan Drug Designation Application Australian Specific Annex to EU Orphan Drug Application 08 June 2017; Qinlock (ripretinib) 50mg tablets; 2019.
• UpToDate Online. Morgan J, et al. Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumours. Available at https://www.uptodate.com/contents/epidemiology-classification-clinical-presentation-prognostic-features-and-diagnostic-work-up-of-gastrointestinal-stromal-tumors-gist. Accessed October 2025.
• von Mehren M, et al. J Clin Oncol. 2018;36(2):136–143.
• Wagner AJ, et al. Mod Pathol. 2013;26(2):289–294.
• Wang Y, Call J. Curr Cancer Drug Targets. 2019;19(9):688–697.
• Yan W, et al. Chin J Cancer. 2016;35(1):68.
• Zhao X, Yue C. J Gastrointest Oncol. 2012;3(3):189–208.

ESMO 2021: Prof. Bauer

• Bauer S, et al. Int J Cancer. 2005;117:316–325.
• Bauer S, et al. Eur J Surg Oncol. 2014;40(4):412–419.
• Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):626–632.
• Casali PG, et al. J Clin Oncol. 2017;35:1713–1720.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Corless CL, et al. J Clin Oncol. 2005;23(23):5357–5364.
• Debiec-Rychter, et al. Eur J Cancer. 2006;42(8):1093–1103.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• Garner AP, et al. Clin Cancer Res. 2014;20(22):5745–5755.
• Heinrich MC. Presented at American Society of Clinical Oncology; 4–8 June 2010; Chicago, Illinois.
• Hornick JL, Fletcher CDM. Hum Pathol. 2007;38(5):679–687.
• Jones RL, et al. Eur J Cancer. 2021;145:132–142.
• MetaGIST. J Clin Oncol. 2010;28(7):1247–1253.
• Miettinen M, et al. Am J Surg Pathol. 2006;30(1):90–96.
• Miettinen M, et al. Am J Surg Pathol. 2011;35(11):1712–1721.
• Mühlenberg T, et al. Mol Cancer Ther. 2019; doi: 0.1158/1535-7163.MCT-18-1224.
• Serrano C, et al. J Clin Oncol. 2015;33(22):e93–96.
• Verweij J, et al. Lancet. 2004;364:1127–1134.
• Wardelmann E, et al. Lancet Oncol. 2005;6:249–251.

ESMO 2021: Prof. Blay

• AYVAKYT^® Summary of Product Characteristics. April 2024.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• ClinicalTrials.gov. NCT01738139. Available at https://clinicaltrials.gov/ct2/show/NCT01738139. Accessed October 2025.
• ClinicalTrials.gov. NCT02216578. Available at https://clinicaltrials.gov/ct2/show/NCT02216578. Accessed October 2025.
• ClinicalTrials.gov. NCT04106024. Available at https://clinicaltrials.gov/ct2/show/NCT04106024. Accessed October 2025.
• ClinicalTrials.gov. NCT04193553. Available at https://clinicaltrials.gov/ct2/show/NCT04193553. Accessed October 2025.
• Cogent. Programs. Available at https://www.cogentbio.com/pipelines-targets/#pipeline. Accessed October 2025.
• Cocco E, et al. Nat Rev Clin Oncol. 2018;15:731–747.
• Doebele RC, et al. Cancer Disc. 2015;5:1049–1057.
• Drilon A, et al. Cancer Discov. 2017;7(9);963–972.
• Drilon A, et al. N Engl J Med. 2018;378:731–739.
• Drilon A. Ann Oncol. 2019;30(Suppl 8):viii23–viii30.
• Drilon A, et al. Presented at American Society of Clinical Oncology; 31 May – 4 June 2019; abstract #2006.
• Gelderblom H, et al. Poster presented at Connective Tissue Oncology Society; 18–21 November 2020; Virtual.
• George S, et al. Oncologist. 2021;26(4):e639–e649.
• Grunewald S, et. Cancer Discov. 2021;11(1):108–125.
• Heinrich MC, et al. Presented at Connective Tissue Oncology Society; 15 November 2019; Tokyo, Japan.
• Heinrich MC, et al. Lancet Oncol. 2020;21:935–946.
• Hong DS, et al. Lancet Oncol. 2020;21(4):531–540.
• Hyman DM, et al. Presented at American Society of Clinical Oncology; 2–6 June 2017; Chicago, IL; LBA2501.
• Jones RL, et al. Eur J Cancer. 2021;145:132–142.
• Jones RL, et al. Presented at European Society for Medical Oncology; 19–21 September 2020; Virtual.
• Kang YK, et al. J Clin Oncol. 2021;39(28):3128–3139.
• Nemunaitis J, et al. Future Oncol. 2020;16(1):4251–4264.
• Neppala P, et al. Cancer Metastasis Rev. 2019;38(3):525–535.
• ROZLYTREK^® Summary of Product Characteristics. March 2025.
• Schöffski P, et al. Eur J Cancer. 2020;134:62–74.
• Smith BD, et al. Cancer Cell. 2019;35:738–751.
• VITRAKVI^® Prescribing Information. April 2025.
• VITRAKVI^® Summary of Product Characteristics. August 2025.
• von Mehren M, et al. BMC Cancer. 2021;21:291.
• von Mehren M, et al. Poster presented at European Society for Medical Oncology; 16–21 September 2021; Virtual.
• Zalcberg J, et al. Presented at European Society for Medical Oncology; 19–21 September 2020; Virtual.